These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Dose adjustment of ciprofloxacin in renal failure: reduce the dose or prolong the administration interval? Czock D; Rasche FM Eur J Med Res; 2005 Apr; 10(4):145-8. PubMed ID: 15946909 [TBL] [Abstract][Full Text] [Related]
30. Dopamine is not an independent risk factor for reduced amikacin clearance in extremely low-birth-weight infants. Allegaert K; Debeer A; Cossey V; Rayyan M; Devlieger H Pediatr Crit Care Med; 2006 Mar; 7(2):143-6. PubMed ID: 16446602 [TBL] [Abstract][Full Text] [Related]
31. Middle-molecule clearance in CRRT: in vitro convection, diffusion and dialyzer area. Messer J; Mulcahy B; Fissell WH ASAIO J; 2009; 55(3):224-6. PubMed ID: 19282753 [TBL] [Abstract][Full Text] [Related]
32. Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients. Isla A; Gascón AR; Maynar J; Arzuaga A; Toral D; Pedraz JL Clin Ther; 2005 May; 27(5):599-608. PubMed ID: 15978309 [TBL] [Abstract][Full Text] [Related]
33. Allometric analysis of ciprofloxacin and enrofloxacin pharmacokinetics across species. Cox SK; Cottrell MB; Smith L; Papich MG; Frazier DL; Bartges J J Vet Pharmacol Ther; 2004 Jun; 27(3):139-46. PubMed ID: 15189299 [TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic interaction of ketoconazole and itraconazole with ciprofloxacin. Abou-Auda HS; Mustafa AA; Al-Humayyd MS Biopharm Drug Dispos; 2008 Jan; 29(1):29-35. PubMed ID: 17943700 [TBL] [Abstract][Full Text] [Related]
35. [Cystatin C, beta2-microglobulin and C-reactive protein in hemodiafiltration and on-line endogenous liquid reinfusion and in low flux polysulphone bicarbonate conventional hemodialysis]. Cristofano C; Vernaglione L; Perniola MA; Lo Barco C; Muscogiuri P; Chimienti S G Ital Nefrol; 2004; 21 Suppl 30():S197-200. PubMed ID: 15750984 [TBL] [Abstract][Full Text] [Related]
36. [Antibiotic use in patients with renal or hepatic failure]. Ramón Azanza J; García E; Sádaba B; Manubens A Enferm Infecc Microbiol Clin; 2009 Dec; 27(10):593-9. PubMed ID: 19853975 [TBL] [Abstract][Full Text] [Related]
37. Surface-modified amikacin-liposomes: organ distribution and interaction with plasma proteins. Bucke WE; Leitzke S; Diederichs JE; Borner K; Hahn H; Ehlers S; Müller RH J Drug Target; 1998; 5(2):99-108. PubMed ID: 9588866 [TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of single-dose intravenous amikacin in critically ill patients undergoing slow hemodialysis. Kihara M; Ikeda Y; Takagi N; Fujita H; Shibata K; Masumori S; Shiratori K; Umemura S; Shionoiri H; Ishii M Intensive Care Med; 1995 Apr; 21(4):348-51. PubMed ID: 7650258 [TBL] [Abstract][Full Text] [Related]
39. High-dose ciprofloxacin for serious gram-negative infection in an obese, critically ill patient receiving continuous venovenous hemodiafiltration. Utrup TR; Mueller EW; Healy DP; Callcut RA; Peterson JD; Hurford WE Ann Pharmacother; 2010 Oct; 44(10):1660-4. PubMed ID: 20736424 [TBL] [Abstract][Full Text] [Related]
40. [Interindividual pharmacokinetic variability in long-term antibiotherapy]. Bourguignon L; Goutelle S; de Saint Martin JB; Guillermet A; Bouniot P; Maire P; Ducher M Med Mal Infect; 2010 Jan; 40(1):38-41. PubMed ID: 19346086 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]